Stoke Therapeutics (NASDAQ:STOK) Insider Sells $58,790.81 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Jason Hoitt sold 1,781 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total value of $58,790.81. Following the sale, the insider owned 12,207 shares in the company, valued at $402,953.07. The trade was a 12.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Jason Hoitt also recently made the following trade(s):

• On Wednesday, March 18th, Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $60,517.54.

Stoke Therapeutics Stock Performance

STOK stock traded up $2.17 during mid-day trading on Thursday, reaching $33.19. 853,428 shares of the stock traded hands, compared to its average volume of 754,489. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $40.22. The stock has a market capitalization of $1.96 billion, a PE ratio of 49.54 and a beta of 1.07. The business has a 50-day moving average price of $32.61 and a two-hundred day moving average price of $29.90.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after purchasing an additional 423,331 shares in the last quarter. Morgan Stanley boosted its position in Stoke Therapeutics by 0.3% during the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after purchasing an additional 9,108 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares in the last quarter. State Street Corp grew its stake in Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after acquiring an additional 1,072,176 shares during the period. Finally, Marshall Wace LLP lifted its holdings in Stoke Therapeutics by 7.9% during the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after purchasing an additional 168,771 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC increased their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Canaccord Genuity Group raised their price target on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Guggenheim initiated coverage on Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.83.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed “buy” with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.